Abstract
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses (< 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
Keywords: Omega-3 PUFAs, high-density lipoprotein, eicosapentaenoic acid and docosahexaenoic acid, atherosclerosis, apolipoproteins, proteome, CVD, coagulation, fibrinolysis
Current Vascular Pharmacology
Title:Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?
Volume: 10 Issue: 4
Author(s): Elena Burillo, Paula Martin-Fuentes, Rocio Mateo-Gallego, Lucia Baila-Rueda, Ana Cenarro, Emilio Ros and Fernando Civeira
Affiliation:
Keywords: Omega-3 PUFAs, high-density lipoprotein, eicosapentaenoic acid and docosahexaenoic acid, atherosclerosis, apolipoproteins, proteome, CVD, coagulation, fibrinolysis
Abstract: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses (< 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
Export Options
About this article
Cite this article as:
Burillo Elena, Martin-Fuentes Paula, Mateo-Gallego Rocio, Baila-Rueda Lucia, Cenarro Ana, Ros Emilio and Civeira Fernando, Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812845
DOI https://dx.doi.org/10.2174/157016112800812845 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dopamine Receptor and Hypertension
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial: Arterial Stiffness, Central Haemodynamics and Non-Alcoholic Fatty Liver Disease: Links with Cardiovascular Risk and Effects of Drug Treatment
Current Vascular Pharmacology Nifedipine Blocks Ondansetron Electrophysiological Effects in Rabbit Purkinje Fibers and Decreases Early Afterdepolarization Incidence
Current Clinical Pharmacology Most Efficient Routes for the Synthesis of α,β-Diamino Acid-Derived Compounds
Current Pharmaceutical Design Cardiovascular Disease: From Diagnosis to Therapy
Current Medicinal Chemistry Stroke-Induced Neurogenesis: Physiopathology and Mechanisms
Current Neurovascular Research Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design Ethyl Acetate and Aqueous Fractions of Ziziphus jujuba Prevent Acute Hypertension Induced by Angiotensin II in Rats
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry The Pharmacological Treatment of Cachexia
Current Drug Targets Quantitative Gait Disturbances in Older Adults with Cognitive Impairments
Current Pharmaceutical Design GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?
Current Vascular Pharmacology Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology Immunosuppression-lipid Metabolism Interplay and Medicinal Plants in Atherosclerosis: A Review
Current Pharmaceutical Design Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Oxidative Stress and Psychological Disorders
Current Neuropharmacology Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Oxidative Stress in Polycystic Ovary Syndrome
Current Pharmaceutical Design Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design